Cue Biopharma (CUE) Expected to Announce Earnings on Monday

Cue Biopharma (NASDAQ:CUE) is anticipated to release its earnings data before the market opens on Monday, April 14th. Analysts expect Cue Biopharma to post earnings of ($0.17) per share and revenue of $1.70 million for the quarter.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. The company had revenue of $1.80 million during the quarter, compared to analysts’ expectations of $1.70 million. Cue Biopharma had a negative return on equity of 156.38% and a negative net margin of 468.02%. During the same quarter in the prior year, the firm posted ($0.28) earnings per share. On average, analysts expect Cue Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cue Biopharma Stock Performance

NASDAQ:CUE opened at $0.68 on Monday. The company has a 50 day simple moving average of $1.16 and a two-hundred day simple moving average of $1.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.22 and a current ratio of 2.22. Cue Biopharma has a fifty-two week low of $0.45 and a fifty-two week high of $2.26. The company has a market capitalization of $42.77 million, a PE ratio of -0.75 and a beta of 2.02.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.